LEGN Legend Biotech Corp

Price (delayed)

$58.93

Market cap

$10.72B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.58

Enterprise value

$9.9B

legend biotech corporation is an emerging company focusing on the development of the best-in-class immunotherapy technology for cancer cure. teamed up with outstanding immunologists and molecular biologists, legend has generated ...

Highlights
The gross profit has grown by 27% from the previous quarter
The EPS has increased by 21% year-on-year and by 12% since the previous quarter
The equity has soared by 78% YoY but it is down by 7% from the previous quarter
The quick ratio has grown by 46% YoY but it has contracted by 20% from the previous quarter
Legend Biotech's debt has increased by 6% YoY

Key stats

What are the main financial stats of LEGN
Market
Shares outstanding
181.91M
Market cap
$10.72B
Enterprise value
$9.9B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
9.21
Price to sales (P/S)
31.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.89
Earnings
Revenue
$342.8M
EBIT
-$445.78M
EBITDA
N/A
Free cash flow
-$323.2M
Per share
EPS
-$2.58
Free cash flow per share
-$1.78
Book value per share
$6.4
Revenue per share
$1.88
TBVPS
$9.74
Balance sheet
Total assets
$1.78B
Total liabilities
$611.05M
Debt
$334.69M
Equity
$1.16B
Working capital
$1.16B
Liquidity
Debt to equity
0.29
Current ratio
5.66
Quick ratio
5.23
Net debt/EBITDA
N/A
Margins
EBITDA margin
N/A
Gross margin
52.4%
Net margin
-135.9%
Operating margin
-93.9%
Efficiency
Return on assets
-25.2%
Return on equity
-36.1%
Return on invested capital
-63.4%
Return on capital employed
-29.2%
Return on sales
-130%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LEGN stock price

How has the Legend Biotech stock price performed over time
Intraday
0.32%
1 week
9.15%
1 month
38.3%
1 year
-21.07%
YTD
-2.06%
QTD
33.05%

Financial performance

How have Legend Biotech's revenue and profit performed over time
Revenue
$342.8M
Gross profit
$179.46M
Operating income
-$321.74M
Net income
-$465.95M
Gross margin
52.4%
Net margin
-135.9%
The operating margin has soared by 81% YoY and by 30% QoQ
Legend Biotech's net margin has surged by 73% YoY and by 25% QoQ
LEGN's operating income is up by 35% year-on-year and by 16% since the previous quarter
The gross profit has grown by 27% from the previous quarter

Growth

What is Legend Biotech's growth rate over time

Valuation

What is Legend Biotech stock price valuation
P/E
N/A
P/B
9.21
P/S
31.27
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
28.89
The EPS has increased by 21% year-on-year and by 12% since the previous quarter
The equity has soared by 78% YoY but it is down by 7% from the previous quarter
The stock's price to book (P/B) is 6% more than its last 4 quarters average of 8.7
The P/S is 52% less than the 5-year quarterly average of 65.8 and 34% less than the last 4 quarters average of 47.1
The revenue is up by 20% since the previous quarter

Efficiency

How efficient is Legend Biotech business performance
The return on sales has surged by 74% year-on-year and by 26% since the previous quarter
The company's return on equity has surged by 63% YoY and by 19% QoQ
LEGN's return on assets is up by 46% year-on-year and by 17% since the previous quarter
LEGN's return on invested capital is up by 44% year-on-year and by 13% since the previous quarter

Dividends

What is LEGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LEGN.

Financial health

How did Legend Biotech financials performed over time
Legend Biotech's total assets is 191% more than its total liabilities
Legend Biotech's current ratio has increased by 47% YoY but it has decreased by 18% QoQ
Legend Biotech's total assets has increased by 47% YoY but it has decreased by 4% from the previous quarter
Legend Biotech's debt is 71% lower than its equity
The equity has soared by 78% YoY but it is down by 7% from the previous quarter
The debt to equity has contracted by 40% YoY but it has grown by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.